NS
Euronext Paris: NANO Nasdaq: NBTX
Nanobiotix is a French clinical-stage biotechnology company developing physics-based therapeutic approaches, including injectable nanoparticles intended to enhance local treatment effects when activated by radiotherapy. Its work targets cancers and aims to expand the potential of established radiation treatment through investigational nanomedicine technologies. The company has clinical research and development activities with external partners, and its programs remain subject to regulatory evaluation. Nanobiotix ordinary shares trade on Euronext Paris under NANO, and its American depositary shares trade on Nasdaq under NBTX.
France
therapeutic nanomedicine · radiation activated nanoparticles
oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →NA
SIX: NOVN NYSE: NVS
Novartis is a Switzerland-based innovative medicines company active in the discovery, development, manufacture and commercialization of prescription treatments. Its official therapeutic-area pages identify cardiovascular, renal and metabolic conditions, immunology, neuroscience and oncology as major areas of focus. It employs multiple therapeutic technologies rather than a single drug-development platform. Official investor materials list ordinary shares on SIX Swiss Exchange under NOVN and American depositary receipts on the New York Stock Exchange under NVS.
Switzerland
small-molecule · biologics · radioligand-therapy
oncology · immunology · neuroscience · cardiometabolic
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →NN
Nasdaq Copenhagen: NOVO B NYSE: NVO
Novo Nordisk is a Denmark-based pharmaceutical company best known for developing and supplying medicines for diabetes, obesity and other serious chronic conditions. Its therapeutic capabilities include peptide and protein-based treatments alongside clinical development and manufacturing. Official investor material lists B shares on Nasdaq Copenhagen and American depositary receipts on the New York Stock Exchange under NVO. These listings refer to the same group and should be mapped as a single issuer.
Denmark
peptide-therapeutics · biologics · metabolic-medicines
diabetes · obesity · cardiometabolic · rare-diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →OT
Nasdaq Capital Market: OBX
Obsidian Therapeutics is a publicly traded biotechnology company developing engineered tumor infiltrating lymphocyte therapies for people with solid tumors. Its research uses regulated protein activity to influence selected functions of modified immune cells, with a focus on investigational cancer treatments. Obsidian became publicly traded in 2026 through a corporate transaction involving Galera Therapeutics. Its current issuer identity and earlier corporate history should be understood together, rather than as separate active public companies.
United States
engineered TIL · regulated cell therapy
solid tumors · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →OP
TSE: 4528
Ono Pharmaceutical is a Japanese prescription-drug company engaged in discovery, clinical development and commercialization of therapies for serious diseases. Its research and development strategy uses small molecules, biologics and selected externally partnered technologies to address oncology, immune conditions and other specialty therapeutic needs. The company also collaborates with academic institutions and biotechnology developers to expand its drug discovery capabilities. Ono is headquartered in Japan and trades on the Tokyo Stock Exchange under ticker 4528.
Japan
small molecules · biologics · oligonucleotide partnerships
oncology · immunology · neurology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →OT
KOSDAQ: 475830
Orum Therapeutics is a South Korean biotechnology company developing targeted therapeutic approaches that combine antibody delivery with protein degradation technologies. Its company FAQ describes degrader-antibody conjugates and a platform intended for treatment of cancers, including hematologic malignancies. The same official source identifies its KOSDAQ listing under 475830. This directory captures a stable issuer identity, scientific platform and disease classification; the current clinical portfolio and experimental results should instead be checked against original company announcements and regulatory records. Listing status remains subject to subsequent exchange updates.
South Korea
antibody-degrader-conjugates · targeted-protein-degradation · antibodies
oncology · hematologic-cancers
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →OH
TSE: 4578
Otsuka Holdings is a Japanese listed holding company whose group businesses include pharmaceutical discovery, development and commercialization alongside other healthcare activities. Its pharmaceutical operations support research into central nervous system disorders, oncology and selected specialty indications through group companies. The parent is based in Japan and trades on the Tokyo Stock Exchange under securities code 4578. This entry describes the listed group's innovative therapeutic business without treating its wider consumer and nutrition businesses as drug development.
Japan
small molecules · biologics · pharmaceutical innovation
central nervous system · oncology · nephrology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →RH
SIX: RO SIX: ROP OTCQX: RHHBY
Roche Holding is a Switzerland-based healthcare group with both pharmaceuticals and diagnostics divisions. It is included here because Roche Pharmaceuticals researches, develops and commercializes innovative treatments, not because its diagnostics business alone qualifies. Corporate material highlights areas including oncology, neuroscience, immunology, ophthalmology, and cardiovascular and metabolic diseases. The company also offers multiple classes of securities, including Swiss bearer shares and participation certificates and an OTC-traded American depositary receipt. These instruments should be represented under one legal issuer rather than as independent biotechnology companies.
Switzerland
biologics · small-molecule · pharmaceuticals
oncology · neurology · immunology · ophthalmology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →SS
Euronext Paris: SAN Nasdaq: SNY
Sanofi is a France-based global biopharmaceutical company active in researching, developing and commercializing innovative medicines and vaccines. Its broad scientific capabilities cover immunology, rare diseases and other therapeutic areas, supported by internal platforms and external research collaborations. The official share-information page confirms ordinary shares on Euronext Paris under SAN and Nasdaq-listed American depositary shares under SNY; these are instruments of the same issuer. Its scientific organization encompasses biologics, vaccines and therapies for immune-related conditions.
France
biologics · small-molecule · vaccines
immunology · rare-diseases · vaccines
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →SF
SSE: 600196 HKEX: 02196
Shanghai Fosun Pharmaceutical is a Chinese healthcare group with research, development, manufacturing and commercialization activities across pharmaceutical medicines and related healthcare businesses. Its innovative therapeutics work includes small-molecule drugs, biological medicines and collaborative development programs in oncology and other disease areas. The issuer is traded on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange, which should be represented as two securities of a single listed group. Fosun Pharma also has businesses outside proprietary drug development, so the directory distinguishes its therapeutics activities from its wider corporate portfolio.
China
small molecules · antibody biologics · cell therapy
oncology · immunology · infectious diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →SJ
SSE STAR: 688180 HKEX: 01877
Shanghai Junshi Biosciences is a China-based innovative biopharmaceutical company focused on discovering and developing therapeutic antibodies and other medicines. Its work includes immuno-oncology, autoimmune and inflammatory diseases, as well as selected infectious-disease programs. The company is associated with the development of toripalimab, an anti-PD-1 antibody, and maintains broader research platforms for antibody engineering and targeted therapies. Junshi has shares listed on the Shanghai Stock Exchange STAR Market under 688180 and on the Hong Kong Stock Exchange under 1877. Both listings refer to the same issuer.
China
monoclonal antibodies · immune checkpoint therapy · antibody-drug conjugates
oncology · immunology · infectious diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →SS
SZSE: 002294
Shenzhen Salubris Pharmaceuticals is a China-based pharmaceutical company engaged in research, development and commercialization of treatments for serious chronic diseases. Its original drug development emphasizes cardiovascular and related conditions, including programs in blood-pressure control, kidney disease and other areas with unmet medical needs. The company combines marketed medicines with research platforms intended to generate new therapies. Salubris trades on the Shenzhen Stock Exchange under stock code 002294 and is headquartered in Shenzhen.
China
small molecules · biologics · cardiovascular therapeutics
cardiovascular · renal disease · metabolic disorders
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →SG
SSE STAR: 688520
Sinocelltech is a Chinese biopharmaceutical company engaged in developing, manufacturing and commercializing biological medicines. Its research activities include monoclonal antibodies, recombinant proteins and vaccines for diseases with significant medical needs. The corporate website identifies its Shanghai STAR Market listing and describes its research platforms, approved products and manufacturing capabilities. The company has worked across therapeutic as well as preventive biologic development. This directory emphasizes the company's issuer identity and long-term technical capabilities without maintaining a full inventory of changing clinical studies or product indications.
China
biologics development
immunology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →S(
SZSE: 300204
Staidson is a Beijing-based biopharmaceutical company engaged in the research, development and commercialization of therapeutic medicines. Its development capabilities include biologic products and other pharmaceutical approaches for diseases with unmet treatment needs. A company-affiliated development program has disclosed research involving a therapeutic biological product for hemophilia, while the wider business includes established prescription medicines. Staidson trades on the Shenzhen Stock Exchange under stock code 300204. Its corporate website identifies the company's principal operating address in Beijing, and exchange filings support the issuer and listed-security information.
China
recombinant proteins · biologics · novel therapeutic development
hematology · neurology · gastroenterology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →SZ
SSE STAR: 688266
Suzhou Zelgen Biopharmaceuticals is a Chinese innovative medicine developer headquartered in Kunshan, Jiangsu province. Its research and pharmaceutical development activities include small-molecule therapies and recombinant protein technologies, with an emphasis on cancers and selected additional diseases. The company conducts drug discovery, clinical research and product development with the objective of bringing proprietary therapeutics into medical use. Its shares are listed on the Shanghai Stock Exchange STAR Market under security code 688266.
China
small molecules · recombinant proteins
oncology · immune-mediated disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →WB
SZSE: 300142
Walvax Biotechnology is a Chinese biotechnology company specializing in vaccine research, product development, manufacturing and commercialization. Its activities span immunization products and investigation of vaccine technologies for the prevention of infectious disease. The company operates an industrial and research platform in China and maintains a portfolio of marketed and investigational vaccines. Walvax is based in Kunming, Yunnan province, and its shares trade on the Shenzhen Stock Exchange under code 300142. Its inclusion is based on proprietary vaccine development rather than distribution or testing services alone.
China
vaccine R&D · recombinant proteins · vaccine manufacturing
infectious diseases · preventive medicine
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →WL
Nasdaq: WVE
Wave Life Sciences is a U.S.-domiciled biotechnology company developing therapeutic technologies that act on RNA. Its research includes RNA editing, gene silencing and other oligonucleotide-based approaches designed to alter disease-related biological pathways. The company has interests in rare genetic disorders and selected metabolic and neurologic diseases. Wave is headquartered operationally in Cambridge, Massachusetts, and its common stock trades on Nasdaq under WVE. Following a 2026 redomiciliation, its Delaware parent succeeded an earlier Singapore-incorporated issuer without creating a second independent listing.
United States
RNA editing · RNA interference · oligonucleotides
rare diseases · metabolic disease · neurology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources → 